Neal D. Shore, MD, FACS, and Chandler Park, MD, share how the POTOMAC data, and a newly FDA-approved combination, are opening up shared decision-making with patients.
Community Insights on Treating High-Risk NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC
2
Active surveillance use for low-risk prostate cancer reaches 93% in VA System
3
HoLEP learning curve and strategies for successful adoption, with Daniel S. Kellner, MD
4
Focal therapy for prostate cancer frequently used outside guideline-supported groups
5